Stock AnalizSummit Therapeutics Inc. SMMT
Biotechnology: Pharmaceutical Preparations · IPO 2015 · data as of November 13, 2026
Summit Therapeutics Inc. (SMMT) is a healthcare company listed in the US with a market value of about $11.3B.
Its overall Stock Analiz score is 0.4 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -124%.
Score: 0.4 / 5
Checks passed
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | $0 | $0 | $705000 | $2M | $860000 | $57M | $36M | $3M | $0 |
| Net income | -$1.1B | -$221M | -$615M | -$79M | -$89M | -$53M | $11M | -$29M | -$27M | -$29M |
| Free cash flow | -$324M | -$142M | -$77M | -$42M | -$73M | -$49M | -$35M | -$21M | $15M | -$25M |
| EPS (diluted) | $-1.35 | $-0.28 | $-0.77 | $-0.10 | $-0.11 | $-0.07 | $0.01 | $-0.04 | $-0.03 | $-0.04 |
| Net margin | — | — | — | -11174.8% | -4897.8% | -6127.6% | 19.0% | -79.3% | -927.6% | — |
| ROIC | — | -57.1% | -331.7% | -8.8% | -100.1% | -66.3% | 7.4% | — | — | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 13 analysts is $29.55, 109% above the current price; targets range from $11.74 to $42.26; the consensus rating is “Buy”; expected EPS is $-0.79 for the fiscal year ending December 31, 2026.
Frequently asked questions
Does Summit Therapeutics pay a dividend?
Not currently.
Is Summit Therapeutics a good stock to buy?
We do not give buy or sell advice. Summit Therapeutics scores 0.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.